In May 2025, researchers at the Buck Institute for Research on Aging and Circulate Health published results from the first placebo-controlled clinical trial of therapeutic plasma exchange (TPE) for biological aging in the journal Aging Cell. The headline: patients who underwent TPE combined with intravenous immunoglobulin (IVIG) experienced a reduction in biological age of 2.61 years on average — measured across 36 validated epigenetic clocks.
This isn’t science fiction. It’s not young blood transfusions. And it’s not the fringe intervention some commentators assumed it was.
Therapeutic plasma exchange is a well-established medical procedure used for decades to treat autoimmune diseases, neurological disorders, and blood conditions. What’s new — and genuinely exciting — is the hypothesis that the same procedure can systematically remove pro-aging factors from the bloodstream and reset aspects of biological age.
Below is the science, the 2025 human data, the legitimate questions that remain, and why Pravida Health has incorporated TPE into its most comprehensive longevity protocols.
What Is Therapeutic Plasma Exchange?
Therapeutic plasma exchange (TPE), also called plasmapheresis, is a procedure in which blood is withdrawn from a patient, the plasma (the liquid component) is separated from the blood cells, the plasma is replaced with a fresh solution — typically albumin with saline, or in some protocols albumin plus IVIG — and the treated blood is returned to the patient.
The procedure takes approximately 2–4 hours per session. Standard medical TPE for autoimmune or neurological conditions uses 5 sessions over 7–14 days. For its established indications, TPE works by removing pathological substances from the blood — autoantibodies in myasthenia gravis, demyelinating antibodies in Guillain-Barré syndrome, paraproteins in multiple myeloma.
The longevity application extends this principle: aging factors — pro-inflammatory proteins, cellular debris, senescent cell secretory products (SASP), dysfunctional clotting factors, and other accumulated molecular “garbage” — also exist in plasma and accumulate with age. Can removing them reset the biological clock? The 2025 data suggests yes, measurably.
The Science: From Mice to Humans
Heterochronic Parabiosis Foundation
The scientific rationale for plasma exchange as an aging intervention traces back to parabiosis research — surgically joining the circulatory systems of young and old mice. These studies, some dating to the 1950s and dramatically advanced by Amy Wagers at Harvard and Irina Conboy at UC Berkeley, consistently showed that exposure to young blood plasma rejuvenated tissues in old mice: muscle repair improved, neurogenesis recovered, liver regeneration normalized.
The flip side also proved true: exposing young mice to old blood plasma caused aging in their tissues.
The critical insight from Conboy’s lab (particularly the 2020 dilution experiments published in Aging): the benefit of young blood may not primarily come from injecting young factors but from removing old ones. When researchers replaced half of old mice’s plasma with saline and albumin — no young factors, just removal of old plasma — the animals showed significant rejuvenation in brain, liver, and muscle tissue.
This reframed the entire intervention. You don’t need young donors. You need to remove the accumulated pro-aging signals your body has built up over decades.
Key Pro-Aging Factors Removed
Research has identified specific plasma proteins that increase with age and drive tissue aging. TPE targets and removes these factors from circulation, replacing them with albumin to reset the inflammatory and signaling environment:
- β2-microglobulin (β2M): Elevated in aged blood; contributes to age-related decline in neurogenesis and hippocampal-dependent cognitive function.
- TGF-β (Transforming Growth Factor-beta): Chronically elevated with age; inhibits muscle stem cell function and impairs liver regeneration.
- Eotaxin: An immune signaling protein elevated in old blood that impairs brain function and cognitive performance.
- PAI-1 (Plasminogen Activator Inhibitor-1): Elevated with age; promotes pro-thrombotic and pro-inflammatory states throughout the vasculature.
- Advanced glycation end-products (AGEs) and glycated proteins: Cross-linking molecules that stiffen tissues and accelerate organ aging.
- SASP factors (IL-6, IL-1β, and related cytokines): Senescence-associated secretory phenotype molecules released by senescent cells that drive systemic inflammation and bystander cell dysfunction.
The 2025 Buck Institute Human Trial
The landmark study, published in Aging Cell on May 28, 2025, was conducted by David Furman, PhD (Buck Institute), Eric Verdin, MD (Buck Institute CEO), and colleagues from Circulate Health. Details of the Buck Institute trial and its multi-omics analysis are publicly available from the Institute.
Design: Single-blind, placebo-controlled trial. 44 adults over age 50, average age approximately 65. Four treatment groups: monthly TPE; biweekly TPE; biweekly TPE + IVIG; and placebo (sham treatment).
Measurement: 36 validated epigenetic clocks across genomic, proteomic, metabolomic, glycomic, and immune system biomarkers — plus physical measures including balance and grip strength.
Key results:
- Monthly TPE group: average biological age reduction of 1.32 years across all epigenetic assessments
- Biweekly TPE + IVIG group: average biological age reduction of 2.61 years
- Placebo group: biological age generally increased during the trial period
- TPE + IVIG modulated cellular senescence-associated proteins and restored age-associated shifts in immune cell composition
- Participants with higher baseline glucose and liver enzyme markers (worse metabolic health) showed the greatest biological age reductions
- Benefits were strongest after initial sessions; diminishing returns with continued treatment suggests optimal spacing protocols need further refinement
Limitations & Contrasting Evidence
This was a small trial — 44 participants — with a relatively short follow-up of 3–6 months. The biological age reductions, while measured with validated tools, do not yet have established correlations to hard clinical outcomes such as reduced mortality or disease incidence. The trial was partially funded by Circulate Health, a commercial entity. Larger, independent, longer-duration trials are needed before definitive clinical recommendations can be made.
A contrasting study published in Scientific Reports (July 2025, PMC12218284) using a different plasmapheresis protocol in a different patient population found no significant epigenetic rejuvenation — and actually observed increases in some aging markers. This highlights the critical importance of protocol specifics. Not all plasma exchange interventions are equivalent, and the choice of replacement solution, session frequency, and patient selection all appear to matter substantially.
The Gap in Standard Care
Therapeutic plasma exchange is widely available in hospital settings — but exclusively for its established medical indications: autoimmune diseases, neurological conditions, blood disorders. It’s covered by insurance for these indications.
For longevity applications, you won’t find this offered by your internist. You won’t find it in conventional preventive medicine. And most academic medical centers are not yet running this outside of clinical trials.
This creates a situation where the most interested patients are seeking out concierge longevity clinics — some of which are applying rigorous clinical protocols, others of which are offering it with minimal monitoring and inflated claims. The gap between the science and the marketing is significant, and patients deserve a physician who can navigate that gap honestly. FDA-approved indications for TPE include Guillain-Barré syndrome, myasthenia gravis, thrombotic thrombocytopenic purpura, and chronic inflammatory demyelinating polyneuropathy. Longevity is an off-label, evidence-informed application in an evolving field.
“The benefit of young blood may not primarily come from injecting young factors but from removing old ones.”
How We Use TPE at Pravida Health
TPE at Pravida is conducted with the same rigor we apply to every intervention: documented clinical rationale, baseline biomarkers, protocol specification, and outcome tracking.
Patient Selection
Our strongest TPE candidates have one or more of the following: elevated biological age markers relative to chronological age on epigenetic testing; significantly elevated inflammatory markers (hsCRP >3.0, elevated IL-6); high visceral fat burden with insulin resistance; high toxic burden on environmental testing; or a family history of neurodegenerative or cardiovascular disease with desire for aggressive primary prevention.
Biological age and inflammatory profiling precede any TPE conversation. Patients whose biological age already tracks closely to chronological age are unlikely to be high-responders, consistent with the Buck trial finding that metabolic dysfunction at baseline predicted the greatest benefit.
Our Protocol
We use a protocol informed by the Circulate Health and Buck Institute approach — albumin-based plasma replacement, sessions spaced monthly initially, with a 4–6 session initial series. Comprehensive biological age monitoring using validated epigenetic clocks is conducted before, at mid-series, and after the treatment course. IVIG addition is considered on a case-by-case basis based on immunological profile and clinical rationale. Contact us to discuss whether IVIG is appropriate for your situation.
What We Measure
Biological age (epigenetic clocks), comprehensive inflammatory panel, proteomics where available, physical performance measures (grip strength, balance), and metabolic markers — all assessed before and after the series. Without this monitoring structure, there is no way to know whether the intervention is working for an individual patient. A practice offering plasma exchange without pre- and post-epigenetic assessment is operating without evidence of effect.
TPE and Environmental Toxins
For patients with documented PFAS, heavy metal, or other environmental toxin accumulation, TPE provides direct removal of plasma-borne toxic compounds alongside its biological age effects. This is particularly relevant given the 2026 Frontiers in Aging data linking elevated PFAS levels to 2–4 years of accelerated epigenetic aging in men 50–64. TPE addresses both the aging signal environment and the toxic burden simultaneously — a dual mechanism that makes it especially compelling for patients with high environmental toxin burden. Learn more about our environmental toxin protocols when you schedule a consultation.
What You Can Do Today
- Understand what TPE is and isn’t. It’s not young blood transfusion. It’s not a cure for aging. It’s a procedure with a growing evidence base for reducing biological age biomarkers — and a plausible, well-characterized mechanism for doing so. Appropriate expectations are essential before entering any protocol.
- Consider TPE in the context of your full longevity biomarker picture. Biological age testing, inflammatory markers, and metabolic assessment should precede any TPE conversation. The Buck trial showed that patients with the highest baseline metabolic dysfunction responded the most. If your biological age already tracks close to chronological, evidence suggests you are not a high-responder.
- Ask about protocol specifics before committing. The 2025 Buck trial and the 2025 Scientific Reports negative study used different protocols and got different results. Protocol matters enormously. Ask what plasma replacement solution is used, how many sessions are recommended, and — critically — how biological age will be tracked before and after.
- Be skeptical of services offering TPE without comprehensive monitoring. A practice offering plasma exchange without pre- and post-epigenetic aging measurement has no way of demonstrating whether the intervention is working for you individually. Monitoring is not optional — it is the mechanism of evidence.
- Watch this space. The VITAL-H trial and ongoing Buck Institute research will generate substantially more evidence over the next 3–5 years. The 2025 data is compelling early evidence — not a finalized clinical recommendation. Staying informed and working with a physician who tracks the literature is your best asset.
Frequently Asked Questions
Is therapeutic plasma exchange the same as young blood transfusions?
No. Young blood transfusion involves infusing plasma from young donors with the intention of adding rejuvenating factors. The FDA banned commercial young blood transfusion in 2019, citing no clinical evidence of benefit and potential harms. TPE replaces plasma with albumin solution — it works by removing pro-aging factors, not by adding young factors. The mechanism is fundamentally different, and the regulatory status is different: TPE is an established, FDA-regulated medical procedure for numerous conditions.
How much does therapeutic plasma exchange cost for longevity purposes?
Individual session costs at longevity clinics typically range from $2,500–$5,000 per session, with longevity protocols recommending 4–6 sessions in an initial series. This is an out-of-pocket expense for longevity applications, as insurance only covers TPE for its established medical indications such as Guillain-Barré syndrome, myasthenia gravis, and thrombotic thrombocytopenic purpura.
What is the evidence that biological age reduction from TPE is meaningful?
A lower biological age as measured by validated epigenetic clocks (GrimAge, DunedinPACE) is associated with lower risk of age-related diseases in epidemiological studies. Whether producing this change through a clinical intervention has the same protective effect as naturally having a lower biological age remains to be established — this is the critical gap between biomarker improvement and hard clinical outcome proof. The 2025 Buck trial is an important step; the hard clinical endpoint trials have not yet been completed.
Are there risks to therapeutic plasma exchange?
TPE is a well-established, generally safe procedure with decades of use in clinical medicine. Risks include hypocalcemia (calcium is removed with plasma, managed with supplementation during the procedure), hypotension, allergic reactions to albumin replacement fluid, infection risk from vascular access, and temporary coagulation changes. Serious complications are uncommon in experienced hands. TPE for longevity is contraindicated in patients with active bleeding disorders, severe cardiovascular instability, or documented albumin allergy.
What is IVIG and why does it enhance the TPE effect?
IVIG (intravenous immunoglobulin) is a concentrated solution of antibodies pooled from thousands of donors. It modulates immune function, has anti-inflammatory properties, and is used in clinical medicine for autoimmune and immunodeficiency conditions. In the Buck Institute trial, adding IVIG to TPE approximately doubled the biological age reduction (2.61 years vs. 1.32 years), possibly because IVIG’s immune recalibration effects complement TPE’s pro-aging factor removal. IVIG addition is not standard for all protocols and is considered on a case-by-case basis.
Is therapeutic plasma exchange right for your longevity protocol?
Pravida Health conducts a full biomarker evaluation — biological age, inflammatory markers, metabolic panel, and environmental toxin assessment — before recommending TPE. We measure first. Then we act on evidence, not guesswork.
Schedule a Consultation